Midday Report: Harvard (HBIO) Shares Fall for August 4

Equities Staff  |

Today Harvard Bioscience Inc. (NASDAQ: HBIO) is trading 5.51% down.

The latest price, as of 11:57:19 est, was $3.60. Harvard has moved $0.21 in trading today.

145,803 shares have exchanged hands.

As of the previous close, Harvard has moved YTD 45.96%. The company anticipates its next earnings on 2022-08-04.

For technical charts, analysis, and more on Harvard visit the company profile.

About Harvard Bioscience Inc.

Harvard Bioscience is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its customers range from renowned academic institutions and government laboratories, to the world's leading pharmaceutical, biotechnology and contract research organizations. With operations in North America, Europe, and China, the company sells through a combination of direct and distribution channels to customers around the world.

To get more information on Harvard Bioscience Inc. and to follow the company's latest updates, you can visit the company's profile page here: Harvard Bioscience Inc.'s Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Trending Articles

The Strong Dollar Is a Problem for Stocks
3 Ways Finance Teams Can Navigate Inflation Through Automation

Market Movers

Sponsored Financial Content